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FINAL EXAMINATION DURATION 
PHA210 – Pharmacology 1 
 
Reading Time: 10 minutes 
Writing Time: 180 minutes 
 
INSTRUCTIONS TO CANDIDATES 
 
This examination has 2 (A and B) Sections: 
Section A contains Forty (40) Multiple Choice Questions.  Answer all questions on the Faculty/School 
supplied Multiple Choice Answer Sheet.  Total marks allocated: Twenty (20). 
Suggested time allocation: One (1) hour. 
Section B contains Ten (10) Extended-Answer Questions.  Answer any Eight (8) questions only in the 
20-page Booklet provided.  Total marks allocated: Eighty (80). 
Suggested time allocation: Two (2) hours. 
EXAM CONDITIONS 
 
You may begin writing from the commencement of the examination session.  The reading time 
indicated above is provided as a guide only. 
This is a CLOSED BOOK examination 
No calculators are permitted 
No handwritten notes are permitted 
No dictionaries are permitted 
ADDITIONAL AUTHORISED MATERIALS EXAMINATION MATERIALS TO BE SUPPLIED 
 
No additional printed material is permitted 
 
1 x 20 Page Book 
1 x Scrap Paper 
Faculty/School Multiple Choice Answer Sheet 
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Section B 
Extended-Answer Questions 
Total No. of Marks for this Section: 80 
Please answer this section in the 20-page Answer Booklet provided.  Ensure that your 
name and student number have been written on the front page of the answer booklet. 
Answer any EIGHT (8) questions. 
Marks for each question are indicated.  Suggested time allocation: 120 mins 
 
Question 1 
Mr SM has been diagnosed with coronary heart disease and is currently taking the 




a. Describe the mechanism of action of the active ingredient in Isomonit 
and explain how it benefits Mr SM? (6 marks) 
b. Comment on the differences in the pharmacokinetics and clinical uses of 
orally administered Isomonit and sublingually administered glyceryl 
trinitrate. 








a. What co-morbidity (additional disorder) is Mr SM likely to be suffering 
from? 
  (1 mark) 
b. Describe the mechanisms of action of the active ingredients in Vytorin. 
  (6 marks) 
c. What are the consequences if Mr SM is not compliant with taking this 
medication? 
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Question 3  






a. Describe the mechanisms of action of the active ingredients in 
Asasantin. 
  (7 marks) 
b. What are the consequences if Mr SM is not compliant with taking this 
medication? 













a. What disorder is Ms PK likely to be suffering from? (1 mark) 
b. Describe the mechanisms of action of the active ingredients in 
COVERSYL PLUS and explain how they resolve Ms PK’s disorder. 
  (7 marks) 
c. Explain the advantages of using this preparation in comparison to 
COVERSYL®, which contains only perindopril arginine. 
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Question 5 (multiple topics) 
a. What is meant by the term ‘pH-dependence’ with respect to local anaesthetics? 
 (5 marks) 
b. Triple therapy (omeprazole, amoxicillin and clarithromycin) is often required for 
the treatment of peptic ulcers.  Describe the mechanism of action of 
omeprazole and explain when this therapy is necessary. 




Mr TP is admitted to the hospital with fatigue, breathlessness and signs of fluid 
retention resulting in oedema.  Medical examinations reveal a cardiomegaly 
(enlarged heart) and reduced ventricular function in the absence of other possible 









a. What disorder is Mr TP likely to be suffering from? (1 mark) 
b. Describe the mechanism of action of the active ingredient in Sigmaxin 
and explain how it improves Mr TP’s signs and symptoms related to his 
disorder. 
  (6 marks) 
c. What kind of adjustment you would make if a loop diuretic was co-
administered to relieve Mr TP’s oedema?  Explain your answer. 
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Question 7 
Describe the mechanism(s) of action and discuss how each of these drugs is useful 
















a. What disorder is Mrs RS likely to be suffering from? (1 mark) 
b. Describe the mechanism(s) of action of the active ingredient in Cordarone 
X and explain how it benefits Mrs RS. 
  (6 marks) 
c. A loading dose of this agent is needed when commencing the treatment.  
Explain what is meant by “loading dose” and the reason for this 
requirement. 
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Question 9 (multiple topics) 
Describe the mechanism(s) of action and the uses of the following drugs in eye 










Question 10  
a. Describe the mechanism of action of heparin and comment on the differences 
in pharmacology between unfractionated and low molecular weight heparin 
(LMWH). 
  (4 marks) 
b. Describe the mechanism of action of warfarin and explain why there is a 
requirement for heparin co-administration when commencing warfarin therapy. 
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